A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Tandutinib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 May 2013 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 May 2012 Planned End Date changed from 1 Jan 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.